Omontys cloud darkens as Takeda pulls EU application
This article was originally published in Scrip
Executive Summary
The future for Omontys (peginesatide), to treat anemia in chronic kidney disease patients on dialysis, is looking even bleaker today after the European Medicines Agency revealed that Takeda has withdrawn its application for marketing authorization.